IDH2 and acute myeloid leukemia: Metabolomic studies have contributed to the discovery and characterization of metabolic abnormalities of AML cells associated with genomic alterations in metabolic enzymes: this was the case of IDH1 and IDH2 mutations leading to the generation of the oncometabolite D-2-hydroxyglutarate [263].